Public Release: 

Long-term effects of tirofiban similar to abciximab in patients having coronary-artery angioplasty

N. B. Please note that if you are outside North America the embargo date for all Lancet press material is 0001hours UK time 2 August 2002

Lancet

A follow-up study in this week's issue of THE LANCET helps to clarify the differences between two similar drugs in terms of their benefits for patients who undergo angioplasty for narrowed coronary arteries (the arteries that supply the heart with blood).

Platelet glycoprotein IIb/IIIa inhibitors reduce the clumping together of platelets in the blood, which can lead to complications during procedures to open narrowed arteries. Tirofiban and abciximab are two such drugs, but each blocks platelet clumping in a slightly different way. Researchers around the world are trying to work out the relevance of these differences with respect to patients' health. Last year, the TARGET investigators showed that abciximab was significantly better than tirofiban at preventing death, heart attacks, and repeated surgery among 4809 patients within 30 days after they had undergone a coronary-artery angioplasty with stent placement.

These investigators, led by Dr David Moliterno from the Cleveland Clinic Foundation, Ohio, USA, now report follow-up data from the TARGET study, which they obtained 6 months after angioplasty. Surprisingly, they found that 14·8% of the patients taking tirofiban had died, had a heart attack, or had repeat surgery, compared with 14·3% of those who took abciximab. In other words, the drugs were about equally effective in terms of preventing these longer-term events.

David Moliterno comments: "As studied, abciximab was more protective against a heart attack occurring during, or immediately following, angioplasty. Yet the two drugs were associated with similarly low rates of death and renarrowing of the heart's arteries at 6 months. Our conclusion is that while the more expensive drug (abciximab) is better 'up front', it provides little long-term advantage compared with tirofiban."

###

Contact: Dr David Moliterno, Department of Cardiovascular Medicine, F-25, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA; T) +1 216 444 2121; F) +1 216 445 4363; E) molited@ccf.org

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.